⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26621647 | 1.00 | — | — | |
| SCHEMBL4771102 | 0.70 | CDC7 (0.36) | — | |
| SCHEMBL4771376 | 0.70 | CDC7 (0.36) | — | |
| SCHEMBL5077969 | 0.69 | — | — | |
| SCHEMBL20841336 | 0.69 | — | — | |
| SCHEMBL24619019 | 0.69 | — | — | |
| SCHEMBL15007205 | 0.67 | CRBN (0.41) | — | |
| SCHEMBL29100868 | 0.66 | — | — | |
| SCHEMBL20881024 | 0.65 | GAA (0.31) | — | |
| SCHEMBL1238782 | 0.64 | CA1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736854-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4055016-B1 | GPR52 MODULATOR COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2026-04-29 | — | — | EP | disclosed |
| EP-4514473-B1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL MYERS SQUIBB CO (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2025-10-16 | — | — | US | disclosed |
| US-12404239-B2 | Modulators of BCL6 as ligand directed degraders | CELGENE CORPORATION (US) | 2025-09-02 | — | — | US | disclosed |
| CN-112424195-B | Fused lactam derivatives | 住友制药株式会社 | 2025-03-25 | — | — | CN | disclosed |
| WO-2025059429-A1 | MODULATORS OF BCL6 FOR USE IN A METHOD OF TREATING A CANCER OR AN AUTOIMMUNE DISEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-03-20 | — | — | WO | disclosed |
| EP-4514473-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Celgene Corporation (US) | 2025-03-05 | — | — | EP | disclosed |
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2023212147-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | CELGENE CORPORATION (US) | 2023-11-02 | — | — | WO | disclosed |
| US-9394297-B2 | Amides as pim inhibitors | AMGEN INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394297-B2 | Amides as pim inhibitors | AMGEN INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394297-B2 | Amides as pim inhibitors | AMGEN INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150329538-A1 | AMIDES AS PIM INHIBITORS | AMGEN INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329538-A1 | AMIDES AS PIM INHIBITORS | AMGEN INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329538-A1 | AMIDES AS PIM INHIBITORS | AMGEN INC. (US) | 2015-11-19 | — | — | US | disclosed |
| WO-2013130660-A1 | AMIDES AS PIM INHIBITORS | AMGEN INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013130660-A1 | AMIDES AS PIM INHIBITORS | AMGEN INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| US-5114461-A | Herbicides | MAY & BAKER LIMITED (GB) | 1992-05-19 | — | — | US | disclosed |
| EP-0278742-A2 | Cyclic diones | MAY & BAKER LIMITED (GB) | 1988-08-17 | — | — | EP | disclosed |